180 related articles for article (PubMed ID: 15660713)
1. Olanzapine in the treatment of resistant depression.
Caetano D; Caetano SC
Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
[No Abstract] [Full Text] [Related]
2. Exacerbation of extrapyramidal symptoms with paroxetine.
Arya DK; McKenzie J; Worrall N
Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063
[No Abstract] [Full Text] [Related]
3. Paroxetine/bupropion combination treatment for refractory depression.
Marshall RD; Liebowitz MR
J Clin Psychopharmacol; 1996 Feb; 16(1):80-1. PubMed ID: 8834426
[No Abstract] [Full Text] [Related]
4. Olanzapine plus venlafaxine in treatment-resistant depression.
Devarajan S; Dursun SM
J Psychopharmacol; 2005 Jul; 19(4):434-5. PubMed ID: 15983004
[No Abstract] [Full Text] [Related]
5. Augmentation of paroxetine with clocapramine in panic disorder.
Saito M; Miyaoka H
Psychiatry Clin Neurosci; 2007 Aug; 61(4):449. PubMed ID: 17610675
[No Abstract] [Full Text] [Related]
6. Addition of olanzapine for treatment-resistant depression.
Pitchot W; Ansseau M
Am J Psychiatry; 2001 Oct; 158(10):1737-8. PubMed ID: 11579017
[No Abstract] [Full Text] [Related]
7. Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.
Gadde KM; Zhang W; Foust MS
J Clin Psychopharmacol; 2006 Aug; 26(4):409-13. PubMed ID: 16855461
[TBL] [Abstract][Full Text] [Related]
8. Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Terao T
Psychiatry Clin Neurosci; 2008 Oct; 62(5):617-9. PubMed ID: 18950384
[TBL] [Abstract][Full Text] [Related]
9. [Paroxetine-induced neuroleptic malignant syndrome].
Heinemann F; Assion HJ; Hermes G; Ehrlich M
Nervenarzt; 1997 Aug; 68(8):664-6. PubMed ID: 9380213
[TBL] [Abstract][Full Text] [Related]
10. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
Abraham JT; Brown R; Meltzer HY
Biol Psychiatry; 1997 Jul; 42(2):144-6. PubMed ID: 9209732
[No Abstract] [Full Text] [Related]
11. Bupropion sustained release: side effect profile.
Settle EC
J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
[TBL] [Abstract][Full Text] [Related]
12. Citalopram-induced diplopia.
Dorell K; Cohen MA; Huprikar SS; Gorman JM; Jones M
Psychosomatics; 2005; 46(1):91-3. PubMed ID: 15765832
[No Abstract] [Full Text] [Related]
13. Withdrawal after discontinuation of paroxetine.
Arya DK
Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
[No Abstract] [Full Text] [Related]
14. Paroxetine: a review of clinical experience.
Dunner D; Kumar R
Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
[TBL] [Abstract][Full Text] [Related]
15. Bupropion-induced psychosis.
Howard WT; Warnock JK
Am J Psychiatry; 1999 Dec; 156(12):2017-8. PubMed ID: 10588428
[No Abstract] [Full Text] [Related]
16. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Menza MA; Dobkin RD; Marin H
J Clin Psychopharmacol; 2007 Apr; 27(2):207-10. PubMed ID: 17414231
[No Abstract] [Full Text] [Related]
17. Should paroxetine be used to treat depression during pregnancy?
Mintzes B; Jureidini J
Am J Psychiatry; 2008 Nov; 165(11):1487; author reply 1487-8. PubMed ID: 18981077
[No Abstract] [Full Text] [Related]
18. Olanzapine treatment in anorexia nervosa: case report.
Dadić-Hero E; Ruzić K; Pernar M; Kabalin M; Medved P
Psychiatr Danub; 2009 Mar; 21(1):122-5. PubMed ID: 19270636
[TBL] [Abstract][Full Text] [Related]
19. Lower gastrointestinal bleeding and paroxetine use: two case reports.
Blasco-Fontecilla H; de Leon J
Psychosomatics; 2012; 53(2):184-7. PubMed ID: 22424167
[No Abstract] [Full Text] [Related]
20. Bupropion: efficacy and safety in the treatment of depression.
Saiz Ruiz J; Gibert J; Gutiérrez Fraile M; Bobes J; Vallejo J; Iglesias C; Iriarte V
Actas Esp Psiquiatr; 2011; 39 Suppl 1():1-25. PubMed ID: 22983817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
